Adjuvant Ipilimumab in High-Risk Uveal Melanoma

Cancers - Switzerland
doi 10.3390/cancers11020152
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Nestin Expression in Primary and Metastatic Uveal Melanoma - Possible Biomarker for High-Risk Uveal Melanoma

Acta Ophthalmologica
MedicineOphthalmology
2018English

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”

Case Reports in Oncological Medicine
Oncology
2019English

Prognosis in Uveal Melanoma

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
1948English

Endoresection With Adjuvant Ruthenium Brachytherapy for Selected Uveal Melanoma Patients - The Tuebingen Experience

Acta Ophthalmologica
MedicineOphthalmology
2016English

Telomerase Expression in Uveal Melanoma

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2000English

GermlineBAP1alterations in Familial Uveal Melanoma

Genes Chromosomes and Cancer
Cancer ResearchGenetics
2016English

Assessing Prognosis in Uveal Melanoma

Cancer Control
MedicineOncologyHematology
2016English

Culturing Uveal Melanoma Cells

Ocular Oncology and Pathology
Nursing
2015English

YAP as Oncotarget in Uveal Melanoma

Oncoscience
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy